Cipla Limited (NSE: CIPLA) and Zydus Lifesciences Ltd (NSE: ZYDUSLIFE) are both listed in the Medicinal Chemicals and Botanical Products industry. Cipla has a market capitalisation of ₹1,12,054 Cr and Zydus Lifesciences ₹1,23,740 Cr, as of 9 Nov 2026. Their P/E ratios are 28.9 and 24.8 respectively. Return on equity is 11.74% for Cipla and 18.32% for Zydus Lifesciences. Over one year, Cipla's share price is down 7.1% and Zydus Lifesciences's is up 23.9%.
| Metric | Cipla | Zydus Lifesciences |
|---|---|---|
| NSE Symbol | CIPLA | ZYDUSLIFE |
| BSE Code | 500087 | 532321 |
| Share Price | ₹1,403.80 | ₹1,215.90 |
| Market Cap | ₹1,12,054 Cr | ₹1,23,740 Cr |
| P/E Ratio | 28.9 | 24.8 |
| Return on Equity | 11.74% | 18.32% |
| Return on Assets | 7.58% | 8.13% |
| Dividend Yield | 0.94% | 0.08% |
| Beta (1Y) | 0.01 | 0.24 |
| 1-Year Price Change | -7.1% | +23.9% |
| 3-Month Price Change | -4.4% | +8.7% |
| 52-Week Range | ₹1,165.70 – ₹1,539.70 | ₹835.50 – ₹1,266.60 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹7,404 Cr | ₹7,910 Cr |
| Quarterly Net Profit | ₹852 Cr | ₹928 Cr |
| Net Margin | 11.5% | 11.7% |
| EPS (Basic, Quarter) | ₹10.86 | ₹9.28 |
| Results Basis | consolidated | consolidated |
| Headquarters | Mumbai, Maharashtra | Ahmedabad, Gujarat |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer’s disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respirator…
Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of onco…
Zydus Lifesciences has a market capitalisation of ₹1,23,740 Cr, against ₹1,12,054 Cr for Cipla as of 9 Nov 2026, about 1.1 times the size by market cap.
Cipla has a P/E of 28.9 and Zydus Lifesciences a P/E of 24.8 as of 9 Nov 2026.
Cipla has a return on equity of 11.74% and Zydus Lifesciences 18.32%.
Cipla's share price is down 7.1% over one year and Zydus Lifesciences's is up 23.9%.
Cipla reported revenue of ₹7,404 Cr and net profit of ₹852 Cr for Q2 FY27. Zydus Lifesciences reported revenue of ₹7,910 Cr and net profit of ₹928 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.